TG Therapeutics Inc. (NASDAQ:TGTX) dropped 3.3% during trading on Thursday . The company traded as low as $5.85 and last traded at $5.87, with a volume of 148,806 shares changing hands. The stock had previously closed at $6.07.

TGTX has been the subject of a number of recent research reports. Brean Capital reiterated a “buy” rating on shares of TG Therapeutics in a research report on Monday, June 13th. FBR & Co restated a “buy” rating on shares of TG Therapeutics in a report on Monday, June 13th. Roth Capital restated a “buy” rating and issued a $33.00 target price on shares of TG Therapeutics in a report on Thursday, June 9th. SunTrust Banks Inc. assumed coverage on TG Therapeutics in a report on Friday, May 27th. They issued a “buy” rating and a $18.00 target price for the company. Finally, Zacks Investment Research lowered TG Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 14th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. TG Therapeutics currently has an average rating of “Buy” and an average target price of $22.33.

The stock’s market capitalization is $317.43 million. The stock has a 50 day moving average of $6.15 and a 200 day moving average of $7.94.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.08. Equities research analysts predict that TG Therapeutics Inc. will post ($1.15) EPS for the current year.

An institutional investor recently raised its position in TG Therapeutics stock. New York State Common Retirement Fund raised its position in TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned about 0.43% of TG Therapeutics worth $2,671,000 at the end of the most recent quarter.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.